TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02099071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 1000 mg
Study: NCT04222517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incisional hernia repair by the mesh implant in sublay retromusuclar position
Description: Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock
Description: Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark).
Study: NCT03422484

Intervention type: OTHER
Intervention: Detection and correction of medication error at hospital admission
Description: Detection and correction of medication error at hospital admission
Study: NCT02099071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02464111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2: Bolus (LNS)
Description: One LNS supplement provided in a single bolus dose in the morning
Study: NCT02099071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00007007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT01761071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
Study: NCT01744145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional 40-60
Description: This group will receive the intervention aged 40-60

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional 60 and above
Description: This group will receive the intervention aged 60 and above.
Study: NCT01758445

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Description: Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol \& physician.
Study: NCT01246466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid: AtriCure Bipolar System & EP ablation procedure
Description: AtriCure Bipolar System plus a catheter ablation
Study: NCT00562900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic assisted cholecystectomy
Description: robotic assisted cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study: NCT00877773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
Study: NCT04153734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
Study: NCT02464111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2: Bolus (LNS)
Description: One LNS supplement provided in a single bolus dose in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2: Bolus (LNS)
Description: One LNS supplement provided in a single bolus dose in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2: Bolus (LNS)
Description: One LNS supplement provided in a single bolus dose in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2: Bolus (LNS)
Description: One LNS supplement provided in a single bolus dose in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2: Bolus (LNS)
Description: One LNS supplement provided in a single bolus dose in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 3: Divided Dose (LNS)
Description: One LNS supplement provided in 3 separate portions throughout the study visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 3: Divided Dose (LNS)
Description: One LNS supplement provided in 3 separate portions throughout the study visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 3: Divided Dose (LNS)
Description: One LNS supplement provided in 3 separate portions throughout the study visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 3: Divided Dose (LNS)
Description: One LNS supplement provided in 3 separate portions throughout the study visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 3: Divided Dose (LNS)
Description: One LNS supplement provided in 3 separate portions throughout the study visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 3: Divided Dose (LNS)
Description: One LNS supplement provided in 3 separate portions throughout the study visit
Study: NCT04213989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus and Conservative Care
Description: A segmental, programmable, gradient advanced pneumatic compression device. The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily. Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Care
Description: May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
Study: NCT02552680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline
Description: Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Manual/brochure containing information about general health
Study: NCT02023138

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focus group
Description: Two hours focus group to allow the participants to modify a clinical practice guideline recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group
Description: Two hours focus group to allow the participants to modify a clinical practice guideline recommendation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wiki
Description: A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wiki
Description: A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
Study: NCT04788290

Intervention type: OTHER
Intervention: Observational
Description: Rabone D®, Once daily administered per the locally approved product information
Study: NCT00440180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg qd for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT04153734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
Study: NCT01185431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ficus carica (Fig paste)
Description: Ficus carica paste 300g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Placebo paste)
Description: Placebo composition 300g/day
Study: NCT03055377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
Study: NCT04369820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: draw blood
Description: 40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
Study: NCT03393533

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I
Description: Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group II
Description: Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
Study: NCT03745820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT04043390

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRP and Molbio Truenat MTB
Description: A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRP and Xpert ULTRA MTB/RIF
Description: A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard test Xpert
Description: The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard test Xpert
Description: The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Culture as reference standard
Description: The investigators will use culture to assess the sensitivity of schemes 1 and 2

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Culture as reference standard
Description: The investigators will use culture to assess the sensitivity of schemes 1 and 2
Study: NCT00724880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is stopped 5 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is stopped 3 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is stopped 0 days prior to surgery
Study: NCT02292784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban
Description: This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
Study: NCT03619811

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reflux Band® Upper Esophageal Sphincter (UES) Assist Device
Description: UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
Study: NCT00348933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine
Description: 200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metafolin
Description: 0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg by mouth per day for all weights and ages
Study: NCT01303003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
Study: NCT02065271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: herbal supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo supplement
Study: NCT02608333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESDM-12
Description: ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: heteregenous as usual community intervention
Study: NCT01991639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and physical activity intervention
Description: Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
Study: NCT03188172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Haematopoietic agent for the stem cell harvest
Study: NCT04322201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter
Description: Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided intermittent large-volume paracentesis
Description: Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
Study: NCT01926327

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Injection of PRP in patients with knee osteoarthritis.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06451731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHOLEXSEM
Description: Phonological, Lexical, and Semantic training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: See arm description
Study: NCT00476567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: standard antenatal care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: specific training program
Description: a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
Study: NCT00972140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol-HFA pMDI 12µg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol-DPI 12 µg twice daily
Study: NCT01659554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75 mg/m2) prepared in 2L normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
Study: NCT01964040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia
Study: NCT03936296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mpMR guided MR-US fusion transrectal prostate biopsy
Description: mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them